chronic heart failure
Conditions
Interventions
Observing during one year after changing to aliskiren 150mg/day from ARB
Sponsors
Anjo Kosei Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patient who is in stable control at registration 2)Patient who is not taking aliskiren within one month before registration 3)Patient who is taking ARB of standard dosage 4)Patient who obtained agreement by free will of patient himself on full understanding after enough explanation
Exclusion criteria
Exclusion criteria: 1)Patient who has hypersensitivity and the past in direct renin inhibitor 2)Patient treated by ACE inhibitor 3)Patient with poor control of diabetic mellitus(HbA1c 9% or more) 4)Patient with unstable angina pectoris or who has the past history of acute myocardial infarction and cerebral infarction within three months 5)Patient with LVEF<30% 6)Patient who has serious liver disease (child classification C or more) 7)Patient who has serious kidney disease 8)Patient who is taking medicine of contraindication of using together 9)Woman who has possibility of pregnancy or getting pregnant 10)Breast-feeding woman 11)Patient with hyperkalemia(5.5mEq/L or more) 12)Patient of eGFR<30mL/min/1.73 m2 13)Additionally, patient who judged to be improper as testee
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in serum brain natriuretic peptide level | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in LVEF,blood pressure,PRA,plasma aldosterone level,serum potassium level,eGFR,serum creatinine level,albuminuria,uric acid level | — |
Countries
Japan
Contacts
Public ContactTadahiro Ito
Anjo Kosei Hospital Division of Cardiovascular Medicine
Outcome results
None listed